Switzerland Based Polares Medical Raises $50M Funding In Series C Round

The round was backed by DC Global Ventures, Lumination Partners, existing investors, and a new strategic investor.

The company will use the proceeds to expand operations and advance its research and development activities.

Read Also - Vivox AI Secures £1.3M To Expand AI Agents For Financial Crime Compliance

Led by CEO Jacques R. Essinger, Polares Medical is developing the MRace Posterior Leaflet Replacement system, a transcatheter therapy designed to treat patients with mitral regurgitation.

“We believe Posterior Leaflet Replacement represents a new chapter in transcatheter mitral therapy,” said Jacques R. Essinger, Ph.D., Chief Executive Officer of Polares Medical. “With over 70 patients of clinical experience and encouraging one-year data demonstrating sustained safety and efficacy, we have established a strong foundation for MRace. This financing positions us to advance the treatment paradigm for complex mitral regurgitation.”

About Polares Medical

Polares Medical SA is a clinical-stage structural heart company developing the MRace Posterior Leaflet Replacement system, a novel transcatheter therapy designed to treat patients suffering from mitral regurgitation.